Vir Biotechnology, Inc. (VIR)
NASDAQ: VIR · Real-Time Price · USD
11.30
-0.45 (-3.83%)
At close: Oct 30, 2026, 4:00 PM EST
11.20
-0.10 (-0.88%)
Pre-market: Nov 2, 2026, 4:18 AM EST
Vir Biotechnology Stock Forecast
Stock Price Forecast
According to 9 analysts polled by S&P Global, Vir Biotechnology stock has a consensus rating of "Strong Buy" and an average price target of $21. The average 1-year stock price forecast is 85.84% higher than the current stock price, while the lowest is $15 (+32.74%) and the highest is $30 (+165.49%).
Price Target: $21 (+85.84%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Vir Biotechnology stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 7 | 7 | 7 | 7 | 6 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 10 | 10 | 10 | 10 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Barclays | Barclays | Buy Maintains $30 | Buy | Maintains | $30 | +165.49% | Oct 19, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $22 | Buy | Reiterates | $22 | +94.69% | Oct 14, 2026 |
| Leerink Partners | Leerink Partners | Buy Reiterates $17 | Buy | Reiterates | $17 | +50.44% | Sep 30, 2026 |
| Needham | Needham | Buy Maintains $18 | Buy | Maintains | $18 | +59.29% | Sep 28, 2026 |
| Bank of America Securities | Bank of America Securities | Buy Reiterates $16 → $15 | Buy | Reiterates | $16 → $15 | +32.74% | Aug 7, 2026 |
Financial Forecast
Revenue This Year
239.48M
from 68.56M
Increased by 249.32%
Revenue Next Year
76.27M
from 239.48M
Decreased by -68.15%
EPS This Year
-1.77
from -3.16
EPS Next Year
-2.47
from -1.77
EPS and Forward PE are based on non-GAAP adjusted numbers.